GlassScriptPhysician profile
Arbi Khemichian
NPI 1003056516
$5,856.47
in general payments reported to CMS, 2019-2025
28 companies · $1,487 in 2025
The $1,487 reported for 2025 was more than what 85% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $759 · 2020: $399 · 2021: $727 · 2022: $963 · 2023: $756 · 2024: $766 · 2025: $1,487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,009.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,008.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $827.73 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $822.46 | 2019-2025 | Cequa |
| Alcon Vision LLC | $795.77 | 2019-2025 | Rocklatan, Tryptyr, Hydrus Microstent |
| Novartis Pharmaceuticals Corporation | $648.10 | 2019-2023 | |
| Allergan, INC. | $635.94 | 2019-2022 | |
| Sight Sciences, INC. | $258.28 | 2021-2025 | Omni Surgical System, Tearcare System |
| Oyster Point Pharma, INC. | $253.70 | 2023-2025 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $173.57 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $173.29 | 2019-2024 | Istent Inject Trabecular Micro-Bypass System Model G2-M-Is, Istent Infinite Trabecular Micro-Bypass System Model Is3, Iaccess Precision Blade |
| Shire North American Group INC | $149.12 | 2019 | |
| Amgen INC. | $137.25 | 2024-2025 | Tepezza |
| Nova Eye, INC. | $102.76 | 2025 | |
| Dompe US, INC. | $100.13 | 2023-2025 | Oxervate |
| Aerie Pharmaceuticals, INC. | $94.42 | 2019-2020 | |
| Johnson & Johnson Surgical Vision, INC. | $94.03 | 2019-2024 | Tecnis Iol, Tecnis Iol, Tecnis Simplicity |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $91.68 | 2024-2025 | Iyuzeh |
| Horizon Therapeutics Plc | $89.91 | 2022-2023 | Tepezza |
| Eyevance Pharmaceuticals LLC | $80.05 | 2019-2022 | |
| Harrow Eye, LLC | $68.02 | 2025 | Vevye |
| Ocular Therapeutix, INC. | $57.61 | 2022-2025 | Dextenza |
| Akorn Operating Company LLC | $43.56 | 2021 | |
| Bausch & Lomb Americas INC. | $38.07 | 2025 | Miebo, Xiidra |
| Ani Pharmaceuticals, INC. | $26.14 | 2025 | Purified Cortrophin Gel |
| Eyepoint US, INC. | $24.96 | 2019 | |
| Omeros Corporation | $19.71 | 2019 | |
| Kala Pharmaceuticals, INC. | $17.99 | 2019 | |
| Akorn, INC. | $16.91 | 2019 | |
| Biotissue Holdings INC. | $15.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arbi Khemichian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.